Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer

Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer - a Two Step Study With a Retrospective Analyses Followed by a Translational Phase II Study

Low dose metronomic chemotherapy (LDMC) in patients with metastatic breast cancer (MBC) is used as a palliative regiment with the aim to prolong and improve quality of life. The effect of LDMC is not fully elucidated. The aim is to evaluate the effect of LDMC with Capecitabine and Cyclophosphamide (CX) and to discover new potential predictive markers and potential markers for monitoring treatment effect.

Inclusion Criteria:

• Written and informed consent
• Breast cancer confirmed by histology
• Recurrence (local or distant) not possible to cure
• Measurable or evaluable disease
• Life expectancy of more than tree months
• ECOG (Eastern Cooperative Oncology Group) performance 0-2
• No or any lines of previous therapies for recurrent disease.
• Adequate contraception for patients of Child bearing age.

Exclusion Criteria:

• Clinically significant cardiovascular disease
• Non healing wound, Active peptic ulcer or bone fracture
• Evidence of any other disease that puts the patient at high risk for treatment-related complications